| Autor: |
Ozer N; Selami Ali Mah. Bakkaladem Sok. Gedikoglu Apt. No: 6/6, Uskudar, Istanbul, 34600, Turkey. drnihatozer@yahoo.com, Cam N, Tangurek B, Ozer S, Uyarel H, Oz D, Guney MR, Ciloglu F |
| Jazyk: |
angličtina |
| Zdroj: |
Heart and vessels [Heart Vessels] 2010 Mar; Vol. 25 (2), pp. 155-62. Date of Electronic Publication: 2010 Mar 26. |
| DOI: |
10.1007/s00380-009-1177-7 |
| Abstrakt: |
In this study, we investigated the contribution of vitamin K epoxide reductase (VKORC1) and cytochrome P450 2C9 (CYP2C9) genotypes, age, and body surface area (BSA) on warfarin dose requirements and in an adult Turkish population. Blood samples were collected from 100 Turkish patients with stable warfarin dose requirements and an international normalized ratio (INR) of the prothrombin time within the therapeutic range. Genetic analyses for CYP2C9 genotypes (*2 and *3 alleles) and VKORC1 -1639 G>A polymorphism were performed and venous INR determined. The mean warfarin daily dose requirement was higher in CYP2C9 homozygous wild-type patients, compared to those with the variant *3 allele (P < 0.05), similar to those with the variant *2 allele (P > 0.05) and highest in patients with the VKORC1 -1639 GG genotype compared to those with the GA genotype and the AA genotype (P < 0.01). The time to therapeutic INR was longer in CYP2C9 homozygous wild-type patients compared with those with the variant *2 and *3 alleles (P < 0.01), and longer in patients with the VKORC1 (position -1639) GG genotype compared with those with the GA genotype and the AA genotype (P < 0.01). The multivariate regression model including the variables of age (R (2) = 4.4%), BSA (R (2) = 27.4%), CYP2C9 (R (2) = 8.1%), and VKORC1 genotype (R (2) = 34.1%) produced the best model for estimating warfarin dose (R (2) = 60.4%). VKORC1 genotype and CYP2C9 polymorphism affect daily dose requirements and time to therapeutic INR in Turkish patients receiving warfarin for anticoagulation. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink